Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: June 5, 2023
During
the
past
decade,
there
has
been
a
revolution
in
cancer
therapeutics
by
emergence
of
antibody-based
immunotherapies
that
modulate
immune
responses
against
tumors.
These
therapies
have
offered
treatment
options
to
patients
who
are
no
longer
responding
classic
anti-cancer
therapies.
By
blocking
inhibitory
signals
mediated
surface
receptors
naturally
upregulated
during
activation
antigen-presenting
cells
(APC)
and
T
cells,
predominantly
PD-1
its
ligand
PD-L1,
as
well
CTLA-4,
such
agents
revolutionized
treatment.
However,
breaking
these
cannot
be
selectively
targeted
tumor
microenvironment
(TME).
Since
physiologic
role
receptors,
known
checkpoints
(IC)
is
maintain
peripheral
tolerance
preventing
autoreactive
IC
inhibitors
(ICI)
induce
multiple
types
immune-related
adverse
effects
(irAEs).
irAEs,
together
with
natural
properties
ICs
gatekeepers
self-tolerance,
precluded
use
ICI
pre-existing
autoimmune
diseases
(ADs).
currently
accumulating
data
indicates
might
safely
administered
patients.
In
this
review,
we
discuss
mechanisms
established
newly
recognized
irAEs
evolving
knowledge
from
application
ADs.
CA A Cancer Journal for Clinicians,
Journal Year:
2020,
Volume and Issue:
70(2), P. 86 - 104
Published: Jan. 16, 2020
Abstract
Cancer
immunotherapies,
including
checkpoint
inhibitors
and
adoptive
cell
therapy,
manipulate
the
immune
system
to
recognize
attack
cancer
cells.
These
therapies
have
potential
induce
durable
responses
in
multiple
solid
hematologic
malignancies
thus
transformed
treatment
algorithms
for
numerous
tumor
types.
immunotherapies
lead
unique
toxicity
profiles
distinct
from
toxicities
of
other
therapies,
depending
on
their
mechanism
action.
often
require
specific
management,
which
can
include
steroids
immune‐modulating
therapy
consensus
guidelines
been
published.
This
review
will
focus
chimeric
antigen
receptor
T
cells,
pathophysiology,
diagnosis,
management.
Nature Communications,
Journal Year:
2020,
Volume and Issue:
11(1)
Published: Oct. 2, 2020
Abstract
Immune-related
adverse
events
(irAEs),
caused
by
anti-PD-1/PD-L1
antibodies,
can
lead
to
fulminant
and
even
fatal
consequences
thus
require
early
detection
aggressive
management.
However,
a
comprehensive
approach
identify
biomarkers
of
irAE
is
lacking.
Here,
we
utilize
strategy
that
combines
pharmacovigilance
data
omics
data,
evaluate
associations
between
multi-omics
factors
reporting
odds
ratio
across
different
cancer
types.
We
bivariate
regression
model
LCP1
ADPGK
accurately
predict
irAE.
further
validate
as
in
an
independent
patient-level
cohort.
Our
provides
method
for
identifying
potential
immunotherapy
using
both
data.
Frontiers in Molecular Biosciences,
Journal Year:
2022,
Volume and Issue:
8
Published: Jan. 10, 2022
Epstein-Barr
virus
(EBV),
also
known
as
human
herpesvirus
4,
is
a
double-stranded
DNA
that
ubiquitous
in
90-95%
of
the
population
gamma
herpesvirus.
It
exists
two
main
states,
latent
infection
and
lytic
replication,
each
encoding
viral
proteins
with
different
functions.
Human
B-lymphocytes
epithelial
cells
are
EBV-susceptible
host
cells.
EBV
latently
infects
B
nasopharyngeal
throughout
life
most
immunologically
active
individuals.
EBV-infected
cells,
free
viruses,
their
gene
products,
abnormally
elevated
titers
observed
cerebrospinal
fluid.
Studies
have
shown
can
infect
neurons
directly
or
indirectly
via
infected
B-lymphocytes,
induce
neuroinflammation
demyelination,
promote
proliferation,
degeneration,
necrosis
glial
proliferative
disorders
B-
T-lymphocytes,
contribute
to
occurrence
development
nervous
system
diseases,
such
Alzheimer's
disease,
Parkinson's
multiple
sclerosis,
acute
cerebellar
ataxia,
meningitis,
disseminated
encephalomyelitis,
brain
tumors.
However,
specific
underlying
molecular
mechanisms
unclear.
In
this
paper,
we
review
role
central
which
could
bebeneficial
providing
new
research
ideas
potential
clinical
therapeutic
targets
for
neurological
diseases.
